Media coverage about Celator Pharmaceuticals (NASDAQ:CPXX) has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celator Pharmaceuticals earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 43.1822460113896 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

COPYRIGHT VIOLATION WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/10/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-celator-pharmaceuticals-cpxx-stock-price-2.html.

Celator Pharmaceuticals Company Profile

Celator Pharmaceuticals, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company’s technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity.

Insider Buying and Selling by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)

Receive News & Ratings for Celator Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celator Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.